14 research outputs found

    Quantitative analytical tools for bee health (Apis mellifera) assessment

    Get PDF
    Background: The number of honeybee (Apis mellifera) colony losses has grown significantly in the past decade, endangering pollination of agricultural crops. Research indicates that no single factor is sufficient to explain colony losses and that a combination of stressors appears to impact hive health. Accurate evaluation of the different factors such as pathogen load, environmental conditions, nutrition and foraging is important to understanding colony loss. Commonly used colony assessment methods are subjective and imprecise making it difficult to compare bee hive parameters between studies. Finding robust, validated methods to assess bees and hive health has become a key area of focus for bee health and bee risk assessment.Results: Our study focused on developing and implementing quantitative analytical tools that allowed us to investigate different factors contribution to colony loss. These validated methods include: adult bee and brood cell imaging and automated counting (IndiCounter, WSC Regexperts), cellular transmitting scales and weather monitoring (Phytech, ILS) and pathogen detection (QuantiGeneĀ® Plex 2.0 RNA assay platform from Affymetrix). These techniques enable accurate assessment of colony state.Conclusion: A major challenge to date for bee health is to identify the events leading to colony loss. Our study describes validated molecular and computational tools to assess colony health that can prospectively describe the etiology of potential diseases and in some cases identify the cause leading to colony collapse.Keywords: colony loss, colony assessment methods, cellular transmitting scales, weather monitoring, QuantiGeneĀ® Plex 2.0

    The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERĪ± expression and enhances hormonal therapy for breast cancer

    Get PDF
    Estrogen receptor-Ī± (ERĪ±)-negative breast cancer is clinically aggressive and does not respond to conventional hormonal therapies. Strategies that lead to re-expression of ERĪ± could sensitize ERĪ±-negative breast cancers to selective ER modulators. FTY720 (fingolimod, Gilenya), a sphingosine analog, is the Food and Drug Administration (FDA)-approved prodrug for treatment of multiple sclerosis that also has anticancer actions that are not yet well understood. We found that FTY720 is phosphorylated in breast cancer cells by nuclear sphingosine kinase 2 and accumulates there. Nuclear FTY720-P is a potent inhibitor of class I histone deacetylases (HDACs) that enhances histone acetylations and regulates expression of a restricted set of genes independently of its known effects on canonical signaling through sphingosine-1-phosphate receptors. High-fat diet (HFD) and obesity, which is now endemic, increase breast cancer risk and have been associated with worse prognosis. HFD accelerated the onset of tumors with more advanced lesions and increased triple-negative spontaneous breast tumors and HDAC activity in MMTV-PyMT transgenic mice. Oral administration of clinically relevant doses of FTY720 suppressed development, progression and aggressiveness of spontaneous breast tumors in these mice, reduced HDAC activity and strikingly reversed HFD-induced loss of estrogen and progesterone receptors in advanced carcinoma. In ERĪ±-negative human and murine breast cancer cells, FTY720 reactivated expression of silenced ERĪ± and sensitized them to tamoxifen. Moreover, treatment with FTY720 also re-expressed ERĪ± and increased therapeutic sensitivity of ERĪ±-negative syngeneic breast tumors to tamoxifen in vivo more potently than a known HDAC inhibitor. Our work suggests that a multipronged attack with FTY720 is a novel combination approach for effective treatment of both conventional hormonal therapy-resistant breast cancer and triple-negative breast cancer

    Flavonoids-Macromolecules Interactions in Human Diseases with Focus on Alzheimer, Atherosclerosis and Cancer

    No full text
    Flavonoids, a class of polyphenols, consumed daily in our diet, are associated with a reduced risk for oxidative stress (OS)-related chronic diseases, such as cardiovascular disease, neurodegenerative diseases, cancer, and inflammation. The involvement of flavonoids with OS-related chronic diseases have been traditionally attributed to their antioxidant activity. However, evidence from recent studies indicate that flavonoidsā€™ beneficial impact may be assigned to their interaction with cellular macromolecules, rather than exerting a direct antioxidant effect. This review provides an overview of the recent evolving research on interactions between the flavonoids and lipoproteins, proteins, chromatin, DNA, and cell-signaling molecules that are involved in the OS-related chronic diseases; it focuses on the mechanisms by which flavonoids attenuate the development of the aforementioned chronic diseases via direct and indirect effects on gene expression and cellular functions. The current review summarizes data from the literature and from our recent research and then compares specific flavonoidsā€™ interactions with their targets, focusing on flavonoid structureā€“activity relationships. In addition, the various methods of evaluating flavonoidā€“protein and flavonoidā€“DNA interactions are presented. Our aim is to shed light on flavonoids action in the body, beyond their well-established, direct antioxidant activity, and to provide insights into the mechanisms by which these small molecules, consumed daily, influence cellular functions

    Regulation of Cholesterol Metabolism by Phytochemicals Derived from Algae and Edible Mushrooms in Non-Alcoholic Fatty Liver Disease

    No full text
    Cholesterol synthesis occurs in almost all cells, but mainly in hepatocytes in the liver. Cholesterol is garnering increasing attention for its central role in various metabolic diseases. In addition, cholesterol is one of the most essential elements for cells as both a structural source and a player participating in various metabolic pathways. Accurate regulation of cholesterol is necessary for the proper metabolism of fats in the body. Disturbances in cholesterol homeostasis have been linked to various metabolic diseases, such as hyperlipidemia and non-alcoholic fatty liver disease (NAFLD). For many years, the use of synthetic chemical drugs has been effective against many health conditions. Furthermore, from ancient to modern times, various plant-based drugs have been considered local medicines, playing important roles in human health. Phytochemicals are bioactive natural compounds that are derived from medicinal plants, fruit, vegetables, roots, leaves, and flowers and are used to treat a variety of diseases. They include flavonoids, carotenoids, polyphenols, polysaccharides, vitamins, and more. Many of these compounds have been proven to have antioxidant, anti-inflammatory, antiobesity and antihypercholesteremic activity. The multifaceted role of phytochemicals may provide health benefits to humans with regard to the treatment and control of cholesterol metabolism and the diseases associated with this disorder, such as NAFLD. In recent years, global environmental climate change, the COVID-19 pandemic, the current war in Europe, and other conflicts have threatened food security and human nutrition worldwide. This further emphasizes the urgent need for sustainable sources of functional phytochemicals to be included in the food industry and dietary habits. This review summarizes the latest findings on selected phytochemicals from sustainable sources—algae and edible mushrooms—that affect the synthesis and metabolism of cholesterol and improve or prevent NAFLD
    corecore